Tenofovir exposure during pregnancy and postpartum in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission of hepatitis B virus Cressey, T. R. Harrison, L. Achalapong, J. Kanjanavikai, P. Ayudhaya, O. P. N. Liampongsabuddhi, P. Siriwachirachai, T. Putiyanun, C. Suriyachai, P. Tierney, C. /Salvadori, Nicolas Chinwong, D. /Decker, Luc Tawon, Y. Murphy, T. V. /Ngo-Giang-Huong, Nicole Siberry, G. K. /Jourdain, Gonzague iTAP Study Team pregnancy tenofovir hepatitis B virus pharmacokinetics We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC(0-24) was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed. 2018 text https://www.documentation.ird.fr/hor/fdi:010074806 fdi:010074806 Cressey T. R., Harrison L., Achalapong J., Kanjanavikai P., Ayudhaya O. P. N., Liampongsabuddhi P., Siriwachirachai T., Putiyanun C., Suriyachai P., Tierney C., Salvadori Nicolas, Chinwong D., Decker Luc, Tawon Y., Murphy T. V., Ngo-Giang-Huong Nicole, Siberry G. K., Jourdain Gonzague, iTAP Study Team. Tenofovir exposure during pregnancy and postpartum in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission of hepatitis B virus. 2018, 62 (12), e01686-18 [5 p.] EN THAILANDE